2cureX AB (2CUREX)
XSTO XSTO Primary Summary
2cureX AB (2CUREX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 2cureX AB ever had a stock split?
2cureX AB Profile
| Biotechnology Industry | Healthcare Sector | Mr. Ole Thastrup VD CEO | XSTO Exchange | SE0010468124 ISIN |
| SE Country | 14 Employees | - Last Dividend | 2 May 2019 Last Split | - IPO Date |
Overview
2cureX AB (publ) is a pioneering medtech company based in Copenhagen, Denmark, established in 2006. Operating primarily within Europe, 2cureX has dedicated its efforts to advancing cancer care through the development of innovative diagnostic solutions. Its core focus lies in enhancing the precision of cancer treatment by predicting the efficacy of various drugs on individual patients, thereby personalizing therapy to improve outcomes. The company engages in rigorous clinical programs targeting colorectal, ovarian, and pancreatic cancers, aiming to expand the utility and applicability of its technologies in the fight against cancer.
Products and Services
2cureX AB (publ) offers a range of products and services designed to revolutionize cancer treatment through personalized medicine. The company's offerings are highlighted below:
- IndiTreat: The flagship product of 2cureX, IndiTreat is an In Vitro Diagnostic (IVD) test that plays a pivotal role in the management of cancer treatment. By assessing a cancer patient’s response to various drugs, IndiTreat enables clinicians to tailor treatment strategies to the individual's specific needs. This not only increases the likelihood of treatment success but also minimizes the risk of adverse effects associated with ineffective therapies. IndiTreat’s utility across different cancer types, including colorectal, ovarian, and pancreatic cancers, showcases its versatility and potential in personalizing cancer care.
- Clinical Programs: Beyond its proprietary IndiTreat test, 2cureX is actively engaged in a series of clinical programs aimed at validating and expanding the use of IndiTreat across a broader spectrum of cancers. These programs are critical in demonstrating the effectiveness of IndiTreat in real-world settings, generating valuable data that supports its adoption in clinical practice. Through its commitment to ongoing research and development, 2cureX is at the forefront of introducing innovative diagnostic solutions that have the potential to significantly impact the field of oncology.
